Patents by Inventor Emile M. Bellott

Emile M. Bellott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS
    Publication number: 20140127137
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: June 17, 2013
    Publication date: May 8, 2014
    Applicant: Cercacor Laboratories, Inc
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors
    Patent number: 8466286
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: June 18, 2013
    Assignee: Cercacor Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS
    Publication number: 20120052018
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: August 22, 2011
    Publication date: March 1, 2012
    Applicant: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors
    Patent number: 8029765
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 4, 2011
    Assignee: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors
    Patent number: 8008088
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: August 30, 2011
    Assignee: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors
    Publication number: 20090004108
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: December 23, 2004
    Publication date: January 1, 2009
    Applicant: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 7342038
    Abstract: The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: March 11, 2008
    Assignees: President and Fellow of Harvard College, Children's Medical Center Corporation, NuChem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6992079
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: January 31, 2006
    Assignees: President Fellows of Harvard College, Children's Medical Center Corporation, NuChem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20040242563
    Abstract: The present invention provides substituted 3,3-phenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: June 1, 2004
    Publication date: December 2, 2004
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Nuchem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6800658
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: October 5, 2004
    Assignees: Children's Medical Center Corporation, President & Fellows of Harvard College, Nuchem Pharmaceuticals, Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20040002486
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: December 7, 2001
    Publication date: January 1, 2004
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20030191111
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 9, 2003
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6534497
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: March 18, 2003
    Assignees: Nuchem Pharmaceuticals, Inc., Children's Medical Center Corporation, Presidents and Fellows of Harvard College
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20020198188
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: January 10, 2002
    Publication date: December 26, 2002
    Applicant: Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
    Publication number: 20020128256
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof which are specific, potent and safe inhibitors of the Ca2+-activated potassium channel (Gardos channel) of erythrocytes. The compounds can be used as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation.
    Type: Application
    Filed: June 13, 2001
    Publication date: September 12, 2002
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
    Publication number: 20020119953
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Application
    Filed: August 28, 2001
    Publication date: August 29, 2002
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellott, Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6127407
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: October 3, 2000
    Assignees: Ion Pharmaceuticals, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6043272
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: March 28, 2000
    Assignees: Ion Pharmaceuticals, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted tryptamines phenalkylamines and related compounds
    Patent number: 5580878
    Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 3, 1996
    Assignee: Interneuron Pharmaceuticals, Inc.
    Inventors: Kay J. D'Orlando, Kenneth W. Locke, Emile M. Bellott, Richard L. Gabriel, Michael D. Nohrden, Yesh P. Sachdeva, Salah A. Zahr, Emile Al-Farhan, Subramaniam Krishnananthan
  • Substituted tryptamines, phenalkylamines and related compounds
    Patent number: 5403851
    Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).
    Type: Grant
    Filed: April 5, 1994
    Date of Patent: April 4, 1995
    Assignee: Interneuron Pharmaceuticals, Inc.
    Inventors: Kay J. D'Orlando, Kenneth W. Locke, Emile M. Bellott, Richard L. Gabriel, Michael D. Nohrden, Yesh P. Sachdeva, Salah A. Zahr, Emile Al-Farhan, Subramaniam Krishnananthan